IL-13Rα2-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of ulcerative colitis

Gut

Volumn 63, Issue 11, 2014, Pages 1728-1736

  Fuss, Ivan J ^a   Joshi, Bharat ^b   Yang, Zhiqiong ^a   Degheidy, Heba ^b   Fichtner Feigl, Stefan ^c   De Souza, Heitor ^d   Rieder, Florian ^d   Scaldaferri, Franco ^d   Schirbel, Anja ^d   Scarpa, Melania ^d   West, Gail ^d   Yi, Chuli ^a   Xu, Lili ^a   Leland, Pamela ^b   Yao, Michael ^a   Mannon, Peter ^a   Puri, Raj K ^b   Fiocchi, Claudio ^d   Strober, Warren ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; GLYCOLIPID; INTERLEUKIN 13 RECEPTOR ALPHA2; PSYCHOSINE; PSYCHOSINE-3'-SULFATE ESTER;

ANALOGS AND DERIVATIVES; HUMAN; IMMUNOLOGY; IN VITRO STUDY; INTESTINE MUCOSA; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER T CELL; ULCERATIVE COLITIS; UPREGULATION;

AUTOANTIGENS; COLITIS, ULCERATIVE; GLYCOLIPIDS; HUMANS; IN VITRO TECHNIQUES; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; INTESTINAL MUCOSA; LYMPHOCYTE SUBSETS; NATURAL KILLER T-CELLS; PSYCHOSINE; UP-REGULATION;

EID: 84893694802     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305671     Document Type: Article

References (21)

1. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-97.
2. Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazalone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002;17:629-38.
3. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550-64.
4. Shamshiev A, Gober HJ, Donda A, et al. Presentation of the same glycolipid by different CD1 molecules. J Exp Med 2002;195:1013-21.
5. Jahng A, Maricic I, Aguillera C, et al. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004;199:947-57.
6. Zajonc DM, Maricic I, Wu D, et al. Structural basis for CD1d presentation of a sulfatide derived from myelin and it's implications for autoimmunity. J Exp Med 2005;202:1517-26.
7. Wu D, Xing GW, Poles MA, et al. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci USA 2005;102:1351-56.
8. Truelove S, Witts LF. Cortisone in ulcerative colitis: a final report on a therapeutic trial. Br Med J 1955;2:1041-46.
9. De Dombal FT, Burton IL, Clamp SE, et al. Short term course and prognosis of Crohn's disease. Gut 1974;15:435-9.
10. Shimamura T, Fujisawa T, Husain SR, et al. Interleukin 13 mediates signal transduction through interleukin 13 receptor α2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer surgery. Clin Cancer Res 2010;16:577-86.
11. Debinski W, Miner R, Leland P, et al. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J Biol Chem 1996;271:22428-33.
12. Joshi BH, Puri RA, Leland P, et al. Identification of interleukin-13 receptor α2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma. Neuro Oncol 2008;10:265-74.
13. Liu Y, Goff RD, Zhou D, et al. A modified α-galactosyl ceramide for staining and stimulating natural killer T cells. J Immunological Methods 2006;312:34-9 (see supplement material online).
14. Roy KC, Maricic I, Khurana A, et al. Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells. J Immunol 2008;180:2942-50.
15. Blomqvist M, Rhost S, Teneberg S, et al. Multiple tissue-specific isoforms of sulfatide activate CD1d-restricted type II NKT cells. Eur J Immunol 2009;39:1726-35.
16. Jansson L, Tobias J, Jarefjäll C, et al. Sulfatide recognition by colonization factor antigen CS6 from enterotoxigenic Escherichia coli. PLoS One 2011;4:e4487.
17. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157: 1261-70.
18. Fichtner-Feigl S, Young CA, Kitani A, et al. IL-13 signaling via IL-13R α2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 2008;135:2003-13.
19. Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006;12:99-106.
20. Kaser A, Lee AH, Franke A, et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008;134:743-56.
21. Olszak T, An D, Zeissig S, et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012;336:489-93.